Monday, April 13, 2020

Mirtogenol® and Glaucoma


After two months of supplementation with Mirtogenol®, the mean IOP decreased from a baseline of 25.2 mmHg to 22.2 mmHg. Nineteen of the twenty patients taking Mirtogenol had a decreased IOP after three months. No side effects were observed. Ocular blood flow improved.
The results of this study indicate that Mirtogenol® may represent a safe preventative intervention for lowering the risk for developing symptomatic glaucoma by controlling IOP and improving ocular blood flow.

No comments:

Post a Comment

Leave a Comment or Question: